Medfield receives research grant from Boehringer Ingelheim
Boehringer Ingelheim International GmbH and Medfield Diagnostics AB have signed a project agreement to “evaluate and test a novel mobile microwave based diagnosis technology for the detection of stroke in pre-hospital and hospital environments”.
Medfield will launch an international multicentre study to generate additional clinical evidence on the ability of the product Strokefinder MD100 to distinguish ischemic stroke from haemorrhagic stroke.
Under the agreement, Boehringer Ingelheim (BI) will co-finance this project. Medfield will retain full ownership of the study and make the results available to BI.
- We are both happy and proud that BI recognizes the potential with Strokefinder. This grant is a welcome contribution on our journey towards market acceptance for our product, says Dag Jungenfelt, CEO at Medfield.
The co-financing from BI is in the form of a 300 k€ grant.
Questions should be addressed to Dag Jungenfelt, CEO, Medfield Diagnostics AB, +46-70-987 28 27 or email@example.com
Medfield Diagnostics AB (publ) in short
Medfield Diagnostics develops microwave diagnostic instruments. First series, Strokefinder is intended to distinguish stroke caused by a clot from stroke caused by bleeding. The need for a rapid diagnostic method for stroke is great since very few patients manage to get the necessary diagnosis and treatment in time. Stroke is currently the third leading cause of death and is one of the main causes of severe and prolonged disabilities in adults. Medfield's patented technology also has other promising areas of application, especially for the diagnosis of traumatic brain injuries.